Theratechnologies enters exclusive licensing agreement with Ionis

Theratechnologies (THTX) announced it has entered into an agreement with Ionis Pharmaceuticals (IONS) to license two investigational RNA-targeted medicines developed by Ionis. Under the agreement, Theratechnologies receives exclusive rights in Canada for olezarsen, which is being evaluated for familial chylomicronemia syndrome and severe hypertriglyceridemia, and for donidalorsen, which is being evaluated for the treatment of hereditary angioedema. All figures are in U.S. dollars unless otherwise stated. Ionis will receive a $10 million upfront payment upon execution of the agreement as well as milestone payments up to $12.75 million based on the achievement of regulatory milestones, public reimbursement, and annual sales targets. Ionis will also be entitled to receive tiered double-digit royalties on annual net sales of each medicine.